New findings offer improved therapy of early-stage, BRCA mutation-associated breast cancer

(Houston Methodist) A new treatment with potential to improve the outcomes for patients with hereditary BRCA mutations and high-risk, early-stage breast cancer appeared June 3 in the New England Journal of Medicine and will be presented June 6 at the 2021 ASCO Annual Meeting. These results represent the first time a PARP inhibitor has been shown to significantly reduce the risk of breast cancer returning in high-risk patients following completion of standard chemotherapy, surgery and radiation therapy.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news